Please login to the form below

Not currently logged in
Email:
Password:

UK biotech leaders partner on science lobbying

The BIA, Bionow, BioPartner and One Nucleus will work together on influencing government policy

UK flagFour of the UK's leading life science groups have formed a partnership to promote bioscience and make policy recommendations to the government.

Under the banner of United Life Sciences the BioIndustry Association (BIA), Bionow, BioPartner and One Nucleus (ON) will work together on issues that it says “directly benefit members and the wider UK sector”. Together these organisations comprise more than 1000 life science and healthcare members.

Steve Bates, CEO of the BIA, said: “Through this collaboration, all four organisations are fully committed to providing a united front and critically, one voice, to the government via the lobbying and advocacy work that the BIA undertakes for the sector.”

The members of United Life Sciences – all of whom have been informally working together for two years – have also contributed to the Life Sciences Manifesto 2015-20.

This manifesto, which was launched at the BIA's UK Bioscience Forum in London this week, highlights key issues for the sector and makes policy recommendations to the government.

Core issues covered in the manifesto include retaining focus of strategically important technologies, such as regenerative medicine and synthetic biology and ensuring a supportive tax and finance environment through continuing policies such as the Biomedical Catalyst and R&D tax credits.

The manifesto also demands support for flexible routes to licensing, evaluation uptake and reimbursement of medicines and treatments to facilitate fast patient access.

United Life Sciences plans to hold a series of UK roadshows to enable early stage companies to access capital, understand the evolving policy landscape and grow their business. It also plans to promote and provide discounts for members on each other's events and work together to provide a combined approach at large international events.

Article by
Kirstie Pickering

9th October 2014

From: Research, Marketing, Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics